ro 22-1319 has been researched along with Basal Ganglia Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, PA; Cohen, JD; Marder, S; Stahl, SM; Van Putten, T | 1 |
1 trial(s) available for ro 22-1319 and Basal Ganglia Diseases
| Article | Year |
|---|---|
The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Double-Blind Method; Humans; Isoquinolines; Male; Middle Aged; Schizophrenia | 1987 |